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CLINICAL SCIENCE
Baseline CD4 Count and Adherence to Antiretroviral
Therapy: A Systematic Review and Meta-Analysis
Peter Bock, MRCP, MPH,* Anelet James, MSC,* Alliance Nikuze, MMedSc,†
Neshaan Peton, Bcur, BTech, MPA,‡ Kalpana Sabapathy, MRCP,§ Edward Mills, PhD, MSc,k
Sarah Fidler, FRCP, PhD,¶ and Nathan Ford, MPH, PhD, FRCPE#**
Background: In light of recent changes to antiretroviral treatment
(ART) guidelines of the World Health Organization and ongoing
concerns about adherence with earlier initiation of ART, we
conducted a systematic review of published literature to review the
association between baseline (pre-ART initiation) CD4 count and
ART adherence among adults enrolled in ART programs worldwide.
Methods: We performed a systematic search of English language
original studies published between January 1, 2004 and September
30, 2015 using Medline, Web of Science, LILACS, AIM, IMEMR,
and WPIMR databases. We calculated the odds of being adherent at
higher CD4 count compared with lower CD4 count according to
study deﬁnitions and pooled data using random effects models.
Results: Twenty-eight articles were included in the review and 18 in
the meta-analysis. The odds of being adherent was marginally lower for
patients in the higher CD4 count group (pooled odds ratio, 0.90; 95%
conﬁdence interval, 0.84 to 0.96); however, the majority of studies found
no difference in the odds of adherence when comparing CD4 count
strata. In analyses restricted to comparisons above and below a CD4
count of 500 cells per microliter, there was no difference in adherence
(pooled odds ratio, 1.01; 95% conﬁdence interval: 0.97 to 1.05).
Conclusions: This review was unable to ﬁnd consistent evidence
of differences in adherence according to baseline CD4 count.
Although this is encouraging for the new recommendations to treat
all HIV-positive individuals irrespective of CD4 count, there is
a need for additional high-quality studies, particularly among adults
initiating ART at higher CD4 cell counts.
Key Words: adherence, antiretroviral therapy, CD4 count, HIV
(J Acquir Immune Deﬁc Syndr 2016;73:514–521)
INTRODUCTION
There are 37 million people living with HIV (PLHIV)
and more than 17 million people on antiretroviral treatment
(ART) globally.1 In 2015, after the publication of ﬁndings from
2 large randomized trials indicating the clinical beneﬁt
of starting ART at any CD4 cell count, the World Health
Organization (WHO) issued updated guidelines recommending
that ART should be started in all HIV-infected adults regard-
less of CD4 count or WHO stage.2–6 Current UNAIDS targets
for HIV treatment scale-up are for 90% of PLHIV to know
their HIV status, 90% of those who know their status to be on
ART, and 90% of those on ART to be virally suppressed.7
Achieving these targets will require rapid further scale-up of
testing and ART initiation and excellent adherence to treat-
ment. Although many factors are known to inﬂuence adher-
ence,8 one frequently raised concern in the context of new
WHO guidelines is the possibility that individuals starting
ART at higher CD4 counts when generally clinically well may
have lower adherence rates.9,10
Although there is strong evidence from individual-
level, randomized, controlled trials for increased patient
beneﬁt when routinely initiating ART at CD4 counts greater
than 500 cells per microliter, there is limited data informing
how ART for all PLHIV will play out in programmatic
settings, where the numbers of individuals receiving care
and level of resources directed at retaining patients and
maximizing adherence is likely to differ from well-resourced
randomized trials. Concern has been expressed about
potential increases in loss to follow-up, ART nonadherence,
sexual disinhibition, and viral resistance among individuals
starting treatment earlier, particularly in high-prevalence
regions where health facilities are often overburdened.11,12
In light of steadily increasing number of adults starting
ART at higher CD4 counts when clinically well and recent
changes to WHO ART guidelines, we conducted a systematic
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review of the published literature that reported the association
between baseline CD4 count and adherence among adult
patients enrolled in ART programs worldwide.
METHODS
Eligibility
As we were interested in the relationship between
baseline CD4 count and adherence in routine program
settings, controlled trials were excluded from review. The
age of 15 years was used for eligibility because this is the
commonly used age cutoff for the management of ART
patients at the “adult clinic” for clinical reasons, including
drug formulation and dosage. Studies reporting on women
starting ART for the prevention of mother-to-child trans-
mission, and use of antiretrovirals for preexposure prophy-
laxis were also excluded because adherence trends in these
populations are not representative of the general population
initiating ART.13,14
Search Strategy and Study Selection
This study has been designed and reported according
to the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) statement.15 We performed
a systematic search of English language, original studies
published between January 1, 2004 and September 30,
2015 for studies reporting on ART adherence among adults
aged $15 years according to baseline CD4 count. A limit
of January 2004 was used to align with the start of the ART
rollout in public health systems in many high-burden
countries. Baseline CD4 count was deﬁned as the most
recent CD4 count reported before initiating ART and the
publishing authors deﬁnition of adherence was used for
each included study. Medline, Web of Science, LILACS,
AIM IMEMR, and WPIMR databases were searched using
a compound search strategy incorporating terms for anti-
retrovirals, adherence, and CD4 count deﬁned in a study
protocol (available from the corresponding author). Pub-
lished abstracts from all Conferences of the International
AIDS Society and the Conference on Retroviruses and
Opportunistic Infections were searched from 2011 to 2015
to identify data that may have been presented but not yet
published in full.
Selection of Studies and Data Extraction
The primary investigator (P.B.) conducted all searches
and reviewed all relevant abstracts, conference presentations,
FIGURE 1. Study selection process.
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and full-length articles. All steps in the search process were
veriﬁed by a second investigator (A.N. or A.J.) (Fig. 1).
Disagreements were resolved through consensus. Data extrac-
tion followed the same veriﬁcation procedure, and it included
patient and program characteristics according to a predeﬁned
data extraction form. Where studies reported both subjective
and objectives measures of adherence, the objective measure
was used based on the assumption that this was likely to be
more accurate. Risk of bias was assessed by the assessment of
the following criteria: (1) objective versus subjective adher-
ence measure, (2) baseline differences (other than CD4 count)
balanced or adjusted for at analysis, (3) prospective versus
retrospective or cross-sectional study design, and (4) and
nondifferential loss to follow-up with respect to likelihood of
being adherent. We used GRADE to assess the overall quality
of the evidence.16
Data Analysis
Our primary effect measure was the odds of being
adherent at higher CD4 count compared with lower CD4
count as deﬁned by the studies. Studies that provided raw data
on the number of adherent patients or odds ratios (ORs) for
adherence by CD4-cell count strata were included in a meta-
analysis that estimated ORs and corresponding 95% conﬁ-
dence intervals (CIs) comparing adherence at lower and
higher CD4 counts at baseline; data were pooled using
a DerSimonian and Laird17 random effects model. Where
studies reported multiple CD4 count group comparisons, we
included data from the comparison of the lowest and highest
CD4 count groups. Where studies reported ORs adjusted for
potential confounders, these estimates were used; otherwise,
crude estimates were used as indicated in Figure 2. Because
the I2 statistic does not work well with observational
studies,18 heterogeneity was assessed by visual inspection of
forest plots. Predeﬁned subgroup analyses were run to explore
potential differences by income status (as deﬁned by World
Bank Income Classiﬁcation)19; we further undertook a post hoc
subgroup analysis to assess the potential inﬂuence of the 2010
WHO guideline change in treatment eligibility (from CD4 200
cells/mL to 350 cells/mL) by assessing differences before and
after 2010. We used STATA version 12.0 (StataCorp LP,
College Station, TX) for all analysis. All P values were 2 sided,
with a P value less than 0$05 regarded as statistically signiﬁcant.
RESULTS
From an initial screen of more than 10,873 abstracts, 27
full-length articles met the inclusion criteria20–46; 1 additional
article was identiﬁed from bibliography screen,47 yielding 28
articles in total included in this review (Fig. 1 and Table 1).
The majority of studies (18) were from low-income and
middle-income countries.20–22,24,25,27–30,33–35,40–44,46 Studies pro-
vided data for 72,119 participants, sample sizes ranged from 76
to 3700 adults, with 31,011 men and 40,669 women included
(1 study did not disaggregate data by sex).46 Median baseline
CD4 count ranged from 104 to 486 cells per microliter and was
FIGURE 2. Forest plot of the odds of
being adherence when comparing
patients who started ART in the
higher CD4 category with those
who start ART in the lower baseline
CD4 category.
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TABLE 1. Overview of Review Studies
First Author
Publication
Year Country Study Type
No.
Participants
Period of
Initiating ART
Abaasa20 2008 Uganda Retrospective cohort 897 2004–2006
Bonolo Pde21 2005 Brazil Prospective cohort 306 Not indicated
Byakika-Tusiime22 2013 Uganda Prospective cohort 76 2002–2007
Carrieri23 2006 France Prospective cohort 1110 1997–1999
Charurat24 2010 Nigeria Retrospective cohort 5760 2005–2006
Chi25 2009 Zambia Retrospective cohort 37,039 2004–2007
Conen26 2013 Switzerland Retrospective cohort 2928 2005–2012
Deloria-Knoll47 2004 United States Cross-sectional survey within cohort 255 March–Nov 1999
Denison27 2015 Tanzania, Uganda, and Zambia Cross-sectional survey within cohort 4489 2004–2010
Diabate28 2007 Cotê d’Ivoire Prospective cohort 591 2005
Elul29 2013 Rwanda Cross-sectional survey within cohort 1951 2002–2007
Gare30 2015 Papua New Guinea Cross-sectional survey within cohort 102 2004–2011
Kyser31 2011 United States Retrospective cohort 528 2004–2006
Lima32 2015 Canada Retrospective cohort 4120 2000–2012
Maqutu33 2010 South Africa Retrospective cohort 688 2004–2006
Maqutu34 2011 South Africa Retrospective cohort 688 2004–2006
Memiah35 2013 Nigeria, Uganda, Zambia, and
Tanzania
Cross-sectional survey within cohort 2344 2004–2005
Merlin36 2012 United States Retrospective cohort 1521 2007–2011
Moore37 2010 Canada Retrospective cohort 1707 2000–2006
Murphy38 2013 United States Retrospective cohort 2090 1994–2002
Palepu39 2006 Canada Retrospective cohort 276 1996–2003
Pefura-Yone40 2013 Cameroon Cross-sectional survey within cohort 889 Before 2011
Ramadhani41 2007 Tanzania Retrospective cohort 150 2005
Rougemont42 2009 Cameroon Prospective cohort 312 2006
Saha43 2014 India Cross-sectional survey within cohort 370 2005–2006
Sarna44 2008 India Cross-sectional survey within cohort 310 2004
Shannon45 2006 Canada Retrospective cohort 184 Before 2002
Weiser46 2014 Uganda Prospective cohort 438 2005–2010
First Author
Minimum Age of
Participant (yrs)
Median Age of
Participant (yrs)
Median Baseline CD4
Cell Count (Cells/mL) Adherence Measure
Adherence
Cutoff (%)
Overall Reported
Adherence (%)
Abaasa20 15 37 Not indicated Self report: VASand pill
count
95 78
Bonolo Pde21 18 Not indicated Not indicated Self report: 3 d recall 95 Not indicated
Byakika-
Tusiime22
15 36 56 Self report: VAS and
number of doses missed
Linear 96
Carrieri23 Not indicated 37 Not indicated Self report: 4 d recall 100 63
Charurat24 Not indicated 35 121 Pharmacy pill count 95 25
Chi25 15 Not indicated 132 MPR based on pharmacy
pill count
100 63
Conen26 16 39 269 Unscheduled treatment
interruption
No interruption
$7 mo
85
Deloria-Knoll47 Not indicated 41 229 and 234 Self report: 3 d recall Not indicated NA
Denison27 18 40 Not indicated Self report: treatment
interruption
No interruption
$48 h
96.8
Diabate28 Not indicated 36 to 39 124 Self report: 4 d recall 95 74
Elul29 18 38 130 to 221 Self report: 3 and 30 d
recall
100 94 and 78 at 3 and
30 d
Gare30 20 Not indicated 264 Self report: 1 mo and pill
count
100 82
Kyser31 18 41 486 Self report: 3 d recall 95 84
Lima32 19 42 Not indicated Pharmacy pill count 95 70 to 80
Maqutu33 Not indicated 32.5 108 Pharmacy pill count 95 79
(continued on next page)
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,200 cells per microliter for 12 studies.21,23,25,27–31,40,43–45
Twenty-seven studies reported adherence as a binary outcome
and one as a linear outcome, detail of which is presented in
Table 1.22 Twelve used ,95% adherence to antiretroviral
doses as a threshold for poor adherence, 2 used ,90%, and 8
used ,100%. Three studies reported on unscheduled treatment
interruption of 2 days, 7 days, and 3 months, respectively.26,27,37
One cross-sectional study used a case index score generated by
a questionnaire of greater than “10” to generate a binary
deﬁnition of adherence versus nonadherence (case index score
,10).40 None of the studies speciﬁcally assessed adherence by
CD4 count as the primary outcome.
Studies varied in their reporting of adherence with
respect to time on ART. The majority of studies in this review
presented multiple pooled estimates of adherence measure-
ments from individuals on ART for durations ranging from 0 to
.7 years. Two studies reported adherence from initiation to
a cutoff time on ART (1 month and 6 months).33,42 A further 9
studies excluded participants on ART for less than 3,24,30
6,27,29,41 or 1223,25,28 months of ART. Where studies reported
adherence at multiple time points, the data at the measurement
taken at the longest duration of ART was used for analysis.
Risk of bias was judged to be moderate based on the
characteristics outlined below (see Supplemental Digital Con-
tent, http://links.lww.com/QAI/A841). Retrospective designs
(21 studies) and subjective measures of adherence (16 studies)
were used most commonly. In the majority (24 studies),
baseline differences other than CD4 counts were balanced at
baseline or adjusted for in analysis; loss to follow-up was
judged to be nondifferential with respect to adherence in 5 of
the 10 studies, where the relevant information was provided.
Overall, the quality of the evidence was judged to be low.
Eighteen studies provided data on 62,823 participants
that could be included in the meta-analysis,20,21,23,24,27–
32,35,36,40,42,44,45,48,49 among which 11 provided adjusted
estimates (Fig. 2).20,23–25,28,29,31,35,36,42,44 Overall, the odds
of being adherent was slightly lower for patients in the
higher CD4 count group (pooled OR, 0$90; 95% CI: 0$84
to 0$96); however, the majority of studies found no
difference in the odds of adherence comparing lower and
higher CD4 count strata, and there was little evidence of
heterogeneity (Fig. 2). Results were not different when
studies were restricted to comparisons above and below
a CD4 count of 200 cells per microliter (pooled OR, 0$88;
95% CI: 0$80 to 0$96) compared with higher thresholds.
When restricting the analysis to studies reporting adherence
above and below 350 cells per microliter, results were again
similar to the overall result (3 studies; pooled OR, 0$85;
95% CI: 0$73 to 0$97)24,35,36; however, 2 of the 3 studies
contributing to this analysis found no difference in adher-
ence.35,36 Two studies compared adherence above and
below 500 cells per microliter and found no difference in
adherence (pooled OR, 1$01; 95% CI: 0$97 to 1.05).31,32
Subgroup analysis by income classiﬁcation found decreased
adherence at higher CD4 counts in low-income and middle-
income countries (OR, 0$88; 95% CI: 0$80 to 0$96),
whereas for high-income countries, there was no difference
(OR, 0$97; 95% CI: 0$87 to 1$07). Studies published before
2010 found decreased adherence at higher CD4 counts (OR,
0.85; 95% CI: 0.76 to 0.93), whereas studies published after
2010 found no difference (OR, 0$97; 95% CI: 0$87
to 1$07).
Five studies from low-income and middle-income set-
tings,22,33,34,41,46 and 5 from high-income settings26,37–39,45 pro-
vided insufﬁcient data for inclusion in the meta-analysis. Of these,
7 studies presented adjusted ORs of the association between
adherence and a numerical baseline CD4 count22,26,33,34,38,39,46; one
presented adjusted ORs of adherence by median baseline CD4
count41 and a further 2 studies37,47 presented a crude comparison
of median baseline CD4 between adherent and nonadherent
TABLE 1. (Continued ) Overview of Review Studies
First Author
Minimum Age of
Participant (yrs)
Median Age of
Participant (yrs)
Median Baseline CD4
Cell Count (Cells/mL) Adherence Measure
Adherence
Cutoff (%)
Overall Reported
Adherence (%)
Maqutu34 Not indicated 32.5 107 Pharmacy pill count 95 58 at 1 mo to 86 at
17 mo
Memiah35 16 38 227 Self report: 7 d recall 95 76
Merlin36 19 44 NA Self report: 2 wk recall 100 71
Moore37 18 39 to 43 150 and 170 Unscheduled treatment
interruption -3 mo
No interruption
$3 mo
61 to 81
Murphy38 18 39 to 41 206 to 221 Self report 95 73–80 across race
groups
Palepu39 Not indicated 35.3 to 36.3 270 and 229 Pharmacy pill count 95 50
Pefura-Yone40 18 40 122 Self report: case index Case index
score .10
78
Ramadhani41 18 41 114 Self report: questionnaire 100 16
Rougemont42 18 37 104 Pharmacy pill count 100 85
Saha43 18 34 241 Self report: 4 d recall 100 88
Sarna44 18 36 to 39 Not indicated Self report: 4 d recall 90 93
Shannon45 16 42 270 Pharmacy pill count 95 30
Weiser46 18 38 137 Self report: VAS 90 61
MPR, medicine possession ratio; VAS, visual analogue scale.
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groups. The results of these studies are presented in Table 2.
Overall median baseline CD4 count ranged from 56 to 270 cells
per microliter, and 6 studies reported a median CD4 count of
,200 cells per microliter.22,33,34,37,41,46 Two studies showed
increased adherence with increased CD4 count (1$01 to 1$14
per 100 cells per microliter increase in baseline CD4 count),26,38 4
studies reported a decrease in adherence at higher CD4
count,22,33,37,39 and 4 reported no difference.34,41,46,47
DISCUSSION
Overall, the ﬁndings of this review showed decreased
adherence at higher baseline CD4 count (OR, 0.90; 95% CI:
0.84 to 0.96), although results were inconsistent across studies.
Of the 28 studies, 15 showed an individual difference with 11
reporting decreased adherence20–24,28,33,37,39,43,44 and 426,27,38,45
reporting increased adherence at higher baseline CD4 count.
The odds of being adherent ranged from 0.58 (95% CI: 0.45 to
0.75)44 to 1.8 (95% CI: 1.22 to 2.91).45 Interpretation of these
ﬁndings is limited by variability in the deﬁnition of higher and
lower CD4 count categories between studies. When studies
were restricted to a threshold of .500 vs #500 cells per
microliter, no differences were observed.
Reported barriers to adherence are multifactorial. A
recent systematic review of the predictors of adherence
identiﬁed a number of factors associated with adherence,
including self-efﬁcacy, substance use, depressive symptoms,
concerns about ART, beliefs about the utility of ART,
satisfaction with the care provider, stigma, and social
support.50 Qualitative studies have identiﬁed a number of
patient-reported barriers to adherence, including forgetful-
ness, limited understanding of the importance of treatment,
drug side effects, pill burden, disruptions to daily routine,
and competing priorities.51 Some studies have reported that
feeling sick is a more frequent barrier to adherence than
feeling healthy52; this may in part be related to the higher pill
burden associated with the treatment of comorbodities.53
The relationship between baseline CD4 count and adherence
to ART is complex and contextual, and other factors are
likely as important or more important in determining
adherence, as suggested by the variability in adherence
levels between studies included in this review. Although
adherence counseling needs to be adapted to respond to the
growing number of people starting ART without having
experienced an illness event, focusing on any single factor
as the cause of poor adherence is unlikely to lead to the
necessary support for patients in a way that will lead to
optimal health outcomes over time.
Strengths of this review include the comprehensive
search of the available literature that allowed us to assess
outcomes among over 72,000 adults initiating ART. Never-
theless, the ﬁndings of this review are judged to be based on
low-quality evidence. This was driven in large part by
differences in CD4 count thresholds and adherence deﬁni-
tions applied between studies, which to a degree reﬂect
differences in ART initiation thresholds applied in different
settings. We present forest plots to display between-study
heterogeneity and used random effects models. Another
limitation with respect to informing current ART guideline
changes is that many of the studies included in this review
were done at a time when ART was initiated at a low
threshold of CD4 count 200 or 350 cells per microliter.2 In
such settings, patients initiating ART at higher CD4 counts
represent speciﬁc patient populations (eg, pregnant women or
tuberculosis-HIV coinfected patients) who may not be
representative of the broader patient population, and only 4
studies adjusted for the presence of WHO deﬁning illness at
ART initiation in the analysis of adherence.23,25,40,42 Duration
of ART may also be an important factor affecting adherence,
although this relationship was inconsistent with some studies
showing an increased adherence over time54 and some
showing a decreased adherence.24,32 Therefore, a further
TABLE 2. Overview of Data From Studies Not Included in the Meta-Analysis
Author Year Country Measure of Baseline CD4
Adjusted
Analysis Association With Adherence
Deloria-Knoll 2004 United States Median CD4 count comparison between
adherent and nonadherent groups
No Mean baseline CD4: adherent group = 378
cells/mL. Nonadherent group = 336
cells/mL; P = 0.18
Byakika-Tusiime 2013 Uganda Numerical baseline CD4 count Yes Adjusted OR, 0.99 (95% CI: 0.997 to 0.999)
Conen 2013 Switzerland Baseline CD4 cell count per
100 cells/mL increase
Yes Adjusted OR, 1.20 (95% CI: 1.14 to 1.26)
Maqutu 2010 South Africa Numerical baseline CD4 count Yes Adjusted OR, 0.995 (95% CI: 0.992 to 0.999)
Maqutu 2011 South Africa Numerical baseline CD4 count Yes Adjusted OR, 1.000 (95% CI: 0.998 to 1.001)
Moore 2010 Canada Median CD4 count comparison between
adherent and nonadherent groups
No Median baseline CD4: adherent group = 150
cells/mL. Nonadherent group = 170
cells/mL; P , 0.001
Murphy 2013 United States Baseline CD4 cell count per
100 cells/mL increase
Yes Adjusted OR, 1.07 (95% CI: 1.01 to 1.14)
Palepu 2006 Canada Baseline CD4 cell count per
100 cells/mL increase
Yes Adjusted OR, 0.90 (95% CI: 0.83 to 0.99)
Ramadhani 2007 Tanzania Baseline median CD4 count Yes Adjusted OR, 1.0 (95% CI: 1.0 to 1.0)
Weiser 2014 Uganda Baseline CD4 cell count per
100 cells/mL increase
Yes Adjusted OR, 0.90 (95% CI: 0.78 to 1.05)
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important limitation is the marked heterogeneity and the lack
of reporting of the duration on ART at which adherence
was measured.
In conclusion, this review was unable to ﬁnd strong
evidence supporting consistent differences in adherence
according to baseline CD4 count, particularly at CD4 counts
.500 cells per microliter. Although this may be encouraging
for the implementation of the new WHO ART guidelines, the
quality of the limited published evidence to date is variable.
Further studies with improved standardization of methods for
monitoring and reporting ART adherence are therefore
encouraged as HIV programs shift toward starting treatment
irrespective of immune status.
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